Oak BioScience is a privately held contract research company serving the life science and pharmaceutical communities. Founded and managed by a group of experienced Silicon Valley biotech veterans, the company aims to help our customers simplify and accelerate biomolecule research and development projects. Our team has extensive experience in molecular biology, antibody engineering, and custom assay development. It’s our goal to bring reliable and affordable research services to the community.
Humanized antibodies reduce human anti-mouse antibody (HAMA) response in patients undergoing antibody therapy against fully murine and chimeric antibodies. Fully humanized monoclonal antibodies are essential in drug development pipelines. Humanized antibodies are designed to reduce HAMA response while maintaining high specificity. They allow for multiple dosing, increased half-life of each dose, and assessment of the human effector function. Oak BioSciences provides antibody humanization service for mouse, rat, rabbit, chicken and camelid monoclonal antibodies. Using our proprietary technologies (extensive antibody database, bioinformatics software, unique antibody humanness score standards) and for rapid production of cell lines expressing full length recombinant antibodies, sequences of the antibody variable domains which determine its binding specificity are incorporated into human donor sequences, creating a panel of full length humanized antibodies for expression.
What We Offer
Phage display is a laboratory technique that uses bacteriophages to associate proteins with their respective genetic information for studying protein–protein, protein–peptide, and protein–DNA interactions. Our scientists have applied this technology to display antibodies for therapeutic protein engineering. Our phage display services allow the selection (“panning”) of recombinant antibody fragments from antibody gene libraries and screening of individually selected antibody clones more convenient and more specific.
Oak BioSciences has developed a pipeline for antibody in vitro affinity maturation based on the principles of mutation and selection (panning). Our in vitro affinity maturation service has successfully been used to optimize antibodies, antibody fragments or other peptide molecules, such as antibody mimetics. Random mutations inside the CDRs are introduced using V-fusion PCR cloning technologies. Chain shuffling is used to increase the genetical diversity. Two or three rounds of mutation and selection (panning) usually results in antibody fragments with affinities in the low nanomolar range (10-1,000 fold increase).
Antibody Isotype/Class Switching
The antibody isotype switching process involves replacing only the constant region of the antibody while maintaining the variable regions, thus maintaining antibody’s specificity. Antibody class switching does not affect antigen specificity, but retains antigen affinity and allows interaction with different effector molecules. Utilizing our proprietary technology and expertise, our scientists are able to modify antibody isotypes from any species to any human IgG isotypes.
Different classes of immunoglobulins, such as IgA, IgD, IgE, IgG and IgM, or subclasses such as different isotype IgGs, possess varying levels of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. Therapeutic antibody development requires selecting a specific class and subclass backbone, based on a desired ADCC and CDC activity profile. To identify optimal ADCC/CDC profiles for specific targets, it is advantageous to study the effects of antibody isotype switching, produced from the same variable region grafted to different class and subclass Fc domains.
Upon request, we will produce chimeric antibodies with different Fc domains using our proprietary cloning cassettes for all antibody classes and subclasses of the human (IgA, IgD, IgM, IgE, IgG1, IgG2, IgG3, and IgG4) and mouse (IgA, IgD, IgM, IgE, IgG1, IgG2a, IgG2b, and IgG3) species.
scFv’s offer multiple advantages over monoclonal antibodies as drug carriers to tumors. They are able to provide greater tumor penetration due to their small size, low kidney uptake, rapid blood clearance, and a lesser negative response by human immune system. Our services include a single-chain variable fragment (scFv) construction service in conjunction with subsequent expression of the novel scFv region on an Fc region for production of a novel antibody via transient expression in mammalian CHO or HEK293 cells.
What We Offer:
Oak BioSciences offers fast and reliable cloning and sequencing services for monoclonal antibodies. Our unique technology allows us to sequence your antibodies from any antibody producing cell line (hybridomas, peripheral blood lymphocytes, B-cells, spleen cells or bone marrow), and from a variety of species (mouse, rat, hamster, rabbit, chicken, camelids, cartilaginous fishes, human and other primates). The service can be tailored to specific parameters, from variable region or domain to full-length antibody sequencing.
Why sequence your monoclonal antibody (mAb)?
What We Offer
Variable Region Cloning and Sequencing
Leader Sequence & Variable Domain Cloning and Sequencing
Full-Length Antibody Cloning and Sequencing
Oak Biosciences Inc has not received any reviews.
Oak Biosciences Inc has not received any endorsements.